Literature DB >> 15198965

Beneficial cardiovascular pleiotropic effects of statins.

Jean Davignon1.   

Abstract

Pleiotropic effects of a drug are actions other than those for which the agent was specifically developed. These effects may be related or unrelated to the primary mechanism of action of the drug, and they are usually unanticipated. Pleiotropic effects may be undesirable (such as side effects or toxicity), neutral, or, as is especially the case with HMG-CoA reductase inhibitors (statins), beneficial. Pleiotropic effects of statins include improvement of endothelial dysfunction, increased nitric oxide bioavailability, antioxidant properties, inhibition of inflammatory responses, and stabilization of atherosclerotic plaques. These and several other emergent properties could act in concert with the potent low-density lipoprotein cholesterol-lowering effects of statins to exert early as well as lasting cardiovascular protective effects. Understanding the pleiotropic effects of statins is important to optimize their use in treatment and prevention of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198965     DOI: 10.1161/01.CIR.0000131517.20177.5a

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  209 in total

1.  Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.

Authors:  Mingxia Gu; Nicholas M Mordwinkin; Nigel G Kooreman; Jaecheol Lee; Haodi Wu; Shijun Hu; Jared M Churko; Sebastian Diecke; Paul W Burridge; Chunjiang He; Frances E Barron; Sang-Ging Ong; Joseph D Gold; Joseph C Wu
Journal:  Eur Heart J       Date:  2014-11-02       Impact factor: 29.983

Review 2.  Statins and their role in pre-percutaneous coronary intervention.

Authors:  Rosetta Melfi; Annunziata Nusca; Giuseppe Patti; Germano Di Sciascio
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

3.  Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia.

Authors:  Liliana Grigore; Sara Raselli; Katia Garlaschelli; Laura Redaelli; Giuseppe D Norata; Angela Pirillo; Alberico L Catapano
Journal:  Eur J Clin Pharmacol       Date:  2012-07-10       Impact factor: 2.953

4.  Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats.

Authors:  Steven D Brooks; Evan DeVallance; Alexandre C d'Audiffret; Stephanie J Frisbee; Lawrence E Tabone; Carl D Shrader; Jefferson C Frisbee; Paul D Chantler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

Review 5.  Statins and the prevention of stroke in diabetes.

Authors:  Mary Ann Banerji
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

6.  Nitric oxide: a key player in the relation between cardiovascular disease and major depressive disorder?

Authors:  Jean-Michel Le Mellédo; Neelam Mahil; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

7.  Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice.

Authors:  S V V S Ramanjaneyulu; P P Trivedi; S Kushwaha; A Vikram; G B Jena
Journal:  J Physiol Biochem       Date:  2013-02-06       Impact factor: 4.158

8.  Influence of rosuvastatin on the NAD(P)H oxidase activity in the retina and electroretinographic response of spontaneously hypertensive rats.

Authors:  P Sicard; N Acar; S Grégoire; B Lauzier; A M Bron; C Creuzot-Garcher; L Bretillon; C Vergely; L Rochette
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

9.  Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.

Authors:  C Cramer; M N Haan; S Galea; K M Langa; J D Kalbfleisch
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

10.  Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals.

Authors:  Alexandre B Rosendo; Luciana O Lima; Felipe Dal-Pizzol; Silvana Almeida
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.